Lupin inks exclusive pact with Visus Therapeutics for YUVEZZI™ in Europe
Lupin's subsidiary VISUfarma B.V. secured exclusive rights to commercialize YUVEZZI™ in Europe from Visus Therapeutics. The deal involves a €20 million investment and up to €55 million in milestone payments, plus royalties. This partnership aims to boost Lupin's ophthalmology portfolio and specialty business in European markets.
The deal involves a significant upfront investment and potential milestone payments, impacting Lupin's financials and market presence in the European ophthalmology sector.
The agreement strengthens Lupin's ophthalmology portfolio and expands its specialty business presence in key European markets with a novel product, YUVEZZI™.
Lupin Limited announced that its wholly-owned subsidiary, VISUfarma B.V. (Netherlands), has entered into an exclusive licensing agreement with Visus Therapeutics, Inc. (U.S.A.) to commercialize YUVEZZI™, a proprietary ophthalmic product for treating Presbyopia in adults. The agreement grants VISUfarma exclusive rights for the European Union, the United Kingdom, Switzerland, Norway, and Iceland.
Under the terms of the agreement, VISUfarma will make a strategic investment of €20 million in Visus through a SAFE instrument. Additionally, Visus Therapeutics and its parent entity will be eligible to receive up to €55 million in regulatory and commercial milestone payments. The agreement also includes provisions for royalty payments based on net sales and sales milestones. The license is valid on a country-by-country basis and will continue until the twentieth anniversary of the first commercial sale, with renewal options for five-year periods.
This collaboration is expected to strengthen Lupin’s ophthalmology portfolio and expand its Specialty Business presence, creating long-term growth opportunities in the Presbyopia treatment market. YUVEZZI™ is a once-daily, dual-agent eye drop approved by the U.S. FDA for the treatment of presbyopia. The transaction does not involve related party transactions.
What to do with a filing like this
Lupin Limited filed this with the NSE as a statutory disclosure, categorised under strategic partnerships. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lupin Limited. Read the original for the full detail.